Ceftaroline Fosamil Patent Expiration

Ceftaroline Fosamil is Used for treating bacterial infections. It was first introduced by Abbvie Inc in its drug Teflaro on Oct 29, 2010. 2 different companies have introduced drugs containing Ceftaroline Fosamil.


Ceftaroline Fosamil Patents

Given below is the list of patents protecting Ceftaroline Fosamil, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Teflaro US6417175 Phosphonocephem derivatives, process for the preparation of the same, and use thereof Dec 17, 2018

(Expired)

Abbvie
Teflaro US6906055 Phosphonocephem compound Dec 15, 2021

(Expired)

Abbvie
Teflaro US7419973 Phosphonocephem compound Dec 15, 2021

(Expired)

Abbvie
Teflaro US8247400 Cephem compounds useful for the treatment of bacterial infections Feb 10, 2031 Abbvie
Teflaro US9629861 Compositions and methods for treating bacterial infections using ceftaroline Sep 21, 2030 Abbvie


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Ceftaroline Fosamil Generics

Several generic applications have been filed for Ceftaroline Fosamil.

Given below is the list of companies who have filed for Ceftaroline Fosamil generic.


1. APOTEX

Apotex Inc has filed for 2 different strengths of generic version for Ceftaroline Fosamil. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
400MG/VIAL powder Discontinued INTRAVENOUS N/A Sep 21, 2021
600MG/VIAL powder Discontinued INTRAVENOUS N/A Sep 21, 2021